Clinical Trial

Pilot Study of Mirtazapine for the Dual Tx of Depression and CINV in High-Grade Glioma Pts on TMZ

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of the study is to estimate the ability of mirtazapine to reduce depression, nausea, and vomiting, and maintain weight in depressed glioma patients undergoing Temozolomide (TMZ) therapy. Of equal importance, the investigators will monitor the tolerability of Mirtazapine in these patients over the course of the study.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2019-04-30; most recent amendment 2025-09-19.
Status change: Recruiting → Active, Not Recruiting 2024-05-13
Trial Details
NCT Number NCT03935685
Lead Sponsor University of California, Irvine
Conditions Glioma of Brain
Enrollment 120 participants
Start Date 2019-02-26
Primary Completion 2030-12-31 (estimated)
Study Completion 2030-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-09-24